Celltrion
Promote the health and welfare of mankind.
Launch date
Employees
Market cap
$33.8b
Enterprise valuation
$35m (Public information from Sep 2024)
Share price
KRW195200 068270.KQ
Incheon South Korea (HQ)
Financials
Estimates*
| KRW | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.8t | 1.9t | 2.3t | 2.2t | 3.6b | 4.4b | 5.3b |
| % growth | 64 % | 2 % | 21 % | (5 %) | (100 %) | 24 % | 20 % |
| EBITDA | 891.0b | 972.0b | 874.0b | 1.0t | 1b | 1.9b | 2.5b |
| % EBITDA margin | 48 % | 51 % | 38 % | 47 % | 28 % | 42 % | 46 % |
| Profit | 511.0b | 575.0b | 533.0b | 535.6b | 550m | 1.3b | 1.7b |
| % profit margin | 28 % | 30 % | 23 % | 25 % | 15 % | 29 % | 32 % |
| EV / revenue | 0.0x | 0.0x | 0.0x | 0.0x | 12.0x | 9.6x | 7.9x |
| EV / EBITDA | 0.1x | 0.0x | 0.0x | 0.0x | 42.9x | 22.5x | 17.0x |
| R&D budget | 171.4b | 125.8b | 139.7b | 161.1b | - | - | - |
| R&D % of revenue | 9 % | 7 % | 6 % | 7 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | N/A | - |
* | $129m | Post IPO Equity | |
$320m | Post IPO Equity | ||
| Total Funding | - | ||
